Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Sutent Label Expansion May Hinge On Disease-Free Survival Stats

Executive Summary

Conflict of interest waivers for US FDA advisory committee review of sunitinib's supplemental application signal that difference in statistical analyses for disease-free survival could be key area of discussion.

You may also be interested in...



Disease-Free Survival In Renal Cancer Raises Questions, But Still Acceptable, ODAC Says

Whether the endpoint can predict overall survival remains unknown, but there is no evidence not to accept it, US FDA advisory committee says.

Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?

US FDA Oncologic Drugs Advisory Committee casts tie vote on proposed expansion of Sutent's renal cell carcinoma indication, mirroring debate FDA having internally.

Pfizer v. Pfizer: Sutent Indication Expansion Will Hinge On Conflicting Trials

US FDA's Oncologic Drugs Advisory Committee will consider whether positive S-TRAC or negative ASSURE data should guide decision on expanding Sutent's renal cell carcinoma indication.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel